Comparative Pharmacology
Head-to-head clinical analysis: CHEWTADZY versus SILDENAFIL CITRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHEWTADZY versus SILDENAFIL CITRATE.
CHEWTADZY vs SILDENAFIL CITRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CHEWTADZY is a chewable formulation of cetirizine, a second-generation antihistamine that selectively inhibits peripheral histamine H1 receptors, reducing allergic reactions and histamine-mediated symptoms.
Sildenafil citrate inhibits phosphodiesterase type 5 (PDE5) in the corpus cavernosum, increasing cGMP levels and enhancing nitric oxide-mediated smooth muscle relaxation, leading to penile erection. It also inhibits PDE5 in pulmonary vasculature, causing vasodilation and reducing pulmonary artery pressure.
2 mg orally twice daily
50 mg orally as needed approximately 1 hour before sexual activity; range 25-100 mg based on efficacy and tolerability; maximum dosing frequency once per day.
None Documented
None Documented
Terminal elimination half-life 12-15 hours, allowing once-daily dosing; prolonged in renal impairment (CrCl <30 mL/min)
Terminal elimination half-life 3-5 hours; clinical effect duration shorter due to distribution.
Primarily renal (55-65% unchanged), biliary/fecal (20-30%), with minor metabolism (<10%)
Approximately 80% fecal, 13% renal as metabolites; <1% unchanged in urine.
Category C
Category A/B
PDE5 Inhibitor
PDE5 Inhibitor